What you should know:
1. Cabozantinib can now be used in patients with hepatocellular carcinoma who were previously treated with sorafenib.
2. Cabozantinib is an orally-delivered drug which inhibits multiple receptors involved in cell function.
3. The FDA first approved the drug in 2012 as a treatment for thyroid cancer. The FDA approved the drug as a renal cancer treatment in 2016.
4. The FDA approved the drug for liver cancer patients based on a phase 3 study. In the study, patients treated with Cabozantinib saw their median survival rate increase 2.2 months.
More articles on gastroenterology:
What GI practices should look for in a PE partner — 5 Qs with Provident’s Abe M’Bodj
84 regional income, case mix benchmarks for ASCs to know
Why an Oklahoma-based ASC values autonomy — 3 insights
